Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer support a planned Phase 3 trial, as the KRAS field grows more crowded.
(Credit: Kyle LaHucik for Endpoints News)
July 2, 2026 11:30 AM EDT
Revolution Medicines shares promising data around KRAS drug combination
Lei Lei Wu
News Reporter
Revolution Medicines' drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial.
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically…
Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use…
CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by…
Few cancers have proven as difficult to treat as pancreatic cancer, making any sign of a survival breakthrough a major event for…
